All 23 RET-mutant MTC patients and 7 RET fusion-positive PTC patients receiving SY-5007 at RP2D were evaluable for efficacy assessment, demonstrating an ORR of 52.2% (12/23, 95% CI 30.6–73.2%) and 42.9% (3/7, 95% CI 9.9–81.6%), and DCR of 91.3% (21/23, 95% CI 72.0–98.9%) and 100.0% (7/7, 95% CI 59.0–100.0%), respectively. This evidence concerns the gene RET and medullary thyroid gland carcinoma.